Orthocell (ASX:OCC) received regulatory approval from Singapore's Health Sciences Authority to market and sell its Striate+ dental membrane for guided bone and tissue regeneration applications in the country, according to a Tuesday filing with the Australian bourse.
The company is on track to receive regulatory clearance for Striate+ in Brazil within three to six months, the filing said.
Shares were up 9% in morning trade Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.